Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rarity within rarity: complete response to chemoimmunotherapy in a patient with polymerase epsilon (POLE)-mutated locally advanced jejunal carcinoma.

The oncologist - 6 Jun 2026

Prisciandaro Michele, Morano Federica, Citterio Davide, Flores Reyes Maria, Barella Marco, Mazzaferro Vincenzo, Pietrantonio Filippo

Abstract excerpt

BACKGROUND: Jejunal carcinoma is an exceptionally rare malignancy with limited therapeutic options beyond chemotherapy. Polymerase epsilon (POLE) mutations in this tumor type are even rarer, yet they may represent a predictive biomarker for response to immune checkpoint inhibitors in jejunal cancer and agnostically. CASE PRESENTATION: We report a 58-year-old male patient diagnosed with a POLE-mutated jejunal...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to DNA Polymerase II

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fluorouracil

Share to POLE gene

Share to Immunotherapy

Share to Mutation

Share to Poly-ADP-Ribose Binding Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 42241221
DOI: 10.1093/oncolo/oyag223
PMCID: PMC13295133

Genes

POLE

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rarity within rarity: complete response to chemoimmunotherapy in a patient with polymerase epsilon (POLE)-mutated locally advanced jejunal carcinoma.PMID 42241221Read ↗

POLE-mutant colon adenocarcinoma – case presentation and histopathological evaluationSemantic proximity Read ↗

The clinical landscape of POLE-mutant colorectal cancer: a retrospective analysis of real-world outcome.Semantic proximity Read ↗

POLE-Mutant Colon Adenocarcinoma-Case Presentation and Histopathological Evaluation.Semantic proximity Read ↗

ctDNA guided management of POLE mutant GI malignancies promotes exceptional responses and prolonged survival to immunotherapy.Semantic proximity Read ↗

High prevalence of unusual KRAS, NRAS, and BRAF mutations in POLE-hypermutated colorectal cancers.Semantic proximity Read ↗

Comprehensive molecular portrait reveals genetic diversity and distinct molecular subtypes of small intestinal neuroendocrine tumorsSemantic proximity Read ↗

Prognosis and treatment response stratification according to loss of proofreading (LOP) POLE variants.Semantic proximity Read ↗

Molecular Advances in Gastrointestinal Pathology.Semantic proximity Read ↗

PD-1 Blockade Elicits Ongoing Remission in Two Cases of Refractory Microsatellite-Stable Cancer Harboring a POLE Mutation.Semantic proximity Read ↗

Morphological, immunophenotypical and molecular features of hypermutation in colorectal carcinomas with mutations in DNA polymerase ε ( POLE )Semantic proximity Read ↗

Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study.Semantic proximity Read ↗

Assessment of POLE and POLD1 mutations as prognosis and immunotherapy biomarkers for stomach adenocarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.